03:00
Improving CAR T Cell Immunotherapy Response to…
Improving CAR T Cell Immunotherapy Response to Diffuse Large B Cell Lymphomas: A Characterization of Metabolic Heterogeneity Across Tumor Models, Tristan Szapary, UG '24 (2278893)
Diffuse Large B Cell Lymphoma (DLBCL) is a prevalent form of blood cancer, with a devasting survival rate of three years. Current treatments begin with aggressive chemotherapy, yet a percentage of…